Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Cardiovascular Toxicity Of Antitumor Drugs: Dimension Of The Problem In Adult Settings

J. Carver, Chaitali J. Desai
Published 2010 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
This paper references
10.1200/JCO.2007.10.9777
American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects.
J. Carver (2007)
10.1634/THEONCOLOGIST.12-3-271
Targeting the microtubules in breast cancer beyond taxanes: the epothilones.
J. Cortés (2007)
10.1136/hrt.2007.123299
Subacute cardiac toxicity following autologous haematopoietic stem cell transplantation in patients with normal cardiac function
T. Chung (2007)
10.1182/blood-2008-03-143537
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.
J. Kiladjian (2008)
10.1001/ARCHINTE.1984.00350210198035
Pericarditis induced by high-dose cytarabine therapy.
L. Vaickus (1984)
10.1056/NEJMOA011795
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
B. E. C. Oiffier (2002)
10.1200/JCO.2002.20.5.1215
Cardiac dysfunction in the trastuzumab clinical trials experience.
A. Seidman (2002)
10.1172/JCI113308
Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity.
R. Diasio (1988)
10.1016/j.ijrobp.2008.04.065
Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer.
F. Bertolini (2009)
10.1200/JCO.2008.26.15_SUPPL.4103
The safety of long-term bevacizumab use: Results from the BRiTE observational cohort study (OCS)
D. Purdie (2008)
10.1002/ART.22025
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
S. Cohen (2006)
10.1200/JCO.2001.19.5.1444
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
G. Batist (2001)
10.1002/cncr.11551
Phase II study of alemtuzumab in chronic lymphoproliferative disorders
A. Ferrajoli (2003)
10.1158/1078-0432.CCR-07-2218
Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade
R. Orlowski (2008)
10.1016/S0140-6736(94)91602-0
Thrombosis with paclitaxel
P. Sevelda (1994)
10.1182/BLOOD.V68.5.1114.BLOODJOURNAL6851114
Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor.
M. Goldberg (1986)
10.1056/NEJMOA032691
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
H. Hurwitz (2004)
10.1001/jama.2008.656
Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.
S. R. Nalluri (2008)
10.1177/000331970605700314
Gemcitabine and Acute Myocardial Infarction
Fadi M Bdair (2006)
10.1200/JCO.2005.01.4092
Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer.
J. Nuver (2005)
10.1080/10428190500158649
Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiation
D. Vogl (2005)
10.1345/aph.1E608
Dyspnea during Thalidomide Treatment for Advanced Ovarian Cancer
M. Gordinier (2005)
10.1182/BLOOD-2002-01-0335
Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.
M. Zangari (2002)
10.1002/cncr.23284
Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma
A. Tarhini (2008)
10.1046/j.0767-3981.2003.00215.x
Vinorelbine‐related cardiac events: a meta‐analysis of randomized clinical trials
M. Lapeyre-Mestre (2004)
10.1016/S0002-9343(88)80094-9
Recombinant alpha 2 interferon-related cardiomyopathy.
M. Cohen (1988)
10.1002/AJH.2830410219
Cytarabine and Cardiac Failure
M. Conrad (1992)
10.1200/JCO.2005.02.129
Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
C. Canil (2005)
10.1159/000072094
Acute Pericarditis and Pleural Effusion Complicating Cytarabine Chemotherapy
A. Gaehler (2003)
10.1056/NEJMOA043445
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
P. Richardson (2005)
10.1634/THEONCOLOGIST.9-1-8
FDA drug approval summaries: oxaliplatin.
A. Ibrahim (2004)
10.1093/eurjhf/hfn012
Cyclophosphamide‐evoked heart failure involves pronounced co‐suppression of cytoplasmic thioredoxin reductase activity and non‐protein free thiol level
X. Wang (2009)
10.1200/JCO.2003.02.018
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
H. Burstein (2003)
10.1200/JCO.2008.18.7252
Bendamustine: rebirth of an old drug.
B. Cheson (2009)
10.1634/THEONCOLOGIST.8-4-303
FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets.
M. Cohen (2003)
10.1056/NEJMOA053028
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
H. Joensuu (2006)
10.1200/JCO.2007.13.9030
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
J. Pignon (2008)
10.1200/JCO.2003.08.013
Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).
G. Sledge (2003)
10.1056/NEJM199103213241205
Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.
S. Lipshultz (1991)
10.1200/JCO.2008.17.7428
Late congestive heart failure after hematopoietic cell transplantation.
S. Armenian (2008)
10.1182/BLOOD-2007-01-070144
Congestive heart failure is a rare event in patients receiving imatinib therapy.
E. Atallah (2007)
10.1634/theoncologist.2008-0143
Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
E. Rivera (2008)
10.3324/HAEMATOL.11127
Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients.
M. Bernengo (2007)
10.1007/s12012-007-0010-8
Ongoing phase I and II studies of novel anthracyclines
C. Sessa (2007)
10.1158/1078-0432.CCR-05-2689
Cardiotoxicity of Histone Deacetylase Inhibitor Depsipeptide in Patients with Metastatic Neuroendocrine Tumors
M. Shah (2006)
10.1158/1078-0432.CCR-0620-3
Vaccination of Cancer Patients Against Telomerase Induces Functional Antitumor CD8+ T Lymphocytes
R. Vonderheide (2004)
10.1158/1078-0432.CCR-03-0627
Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias
J. Karp (2004)
10.1056/NEJM200106213442516
Deep venous thrombosis and thalidomide therapy for multiple myeloma.
K. Osman (2001)
10.1200/JCO.2007.12.1665
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.
H. Mouridsen (2007)
10.1200/JCO.1994.12.1.14
Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer.
T. Buroker (1994)
10.1056/NEJMOA060655
Sorafenib in advanced clear-cell renal-cell carcinoma.
B. Escudier (2007)
10.1200/JCO.2008.18.7658
First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.
A. Inoue (2009)
10.1200/JCO.1998.16.10.3257
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.
J. Lundin (1998)
10.1111/j.1365-2141.2008.07165.x
Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation
A. Tichelli (2008)
10.1093/ANNONC/MDI147
Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study.
A. González-Martín (2005)
10.1016/S1470-2045(06)70767-7
Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.
A. Buzdar (2006)
10.7326/0003-4819-91-5-710
Risk factors for doxorubicin-induced congestive heart failure.
D. V. Von Hoff (1979)
10.1016/J.HEALUN.2007.04.012
Alemtuzumab (Campath 1H) as successful salvage therapy for recurrent steroid-resistant heart transplant rejection.
K. Woodside (2007)
10.1200/JCO.1990.8.1.170
High-dose ifosfamide with mesna uroprotection: a phase I study.
A. Elias (1990)
10.1002/cncr.22596
Results of a Phase II trial of oral bexarotene (Targretin) combined with interferon alfa‐2b (Intron‐A) for patients with cutaneous T‐cell lymphoma
D. Straus (2007)
10.1093/JNCI/81.1.59
Myocardial toxic effects during recombinant interleukin-2 therapy.
R. Nora (1989)
10.1158/1078-0432.CCR-05-2095
Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell Lymphoma
R. Piekarz (2006)
10.3816/CBC.2002.S.004
Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results.
J. O'Shaughnessy (2002)
10.1056/NEJMOA062867
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
B. Druker (2006)
10.1007/S12094-008-0201-1
Complete atrioventricular block induced by rituximab in monotherapy in an aged patient with non-Hodgkin’s diffuse large B-cell lymphoma
José Manuel Cervera Grau (2008)
10.1016/S1470-2045(08)70003-2
Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis.
S. Wu (2008)
10.3816/CLM.2008.n.035
Acute coronary syndromes complicating the first infusion of rituximab.
J. Armitage (2008)
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
P. F. Bross (2001)
10.1200/JCO.2007.12.5070
Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.
J. Friedberg (2008)
10.1016/J.AMJMED.2004.03.040
Adverse effects of thalidomide administration in patients with neoplastic diseases.
M. Dimopoulos (2004)
10.1093/annonc/mdn431
Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma.
J. Lee (2008)
Capecitabine cardiotoxicity--case reports and literature review.
N. Manojlovic (2008)
10.1200/JCO.1998.16.11.3537
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.
E. Levy (1998)
10.1016/j.leukres.2008.03.020
An evaluation of the cardiotoxicity of imatinib mesylate.
A. Ribeiro (2008)
10.1200/JCO.1999.17.7.2081
Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial.
L. Crinò (1999)
10.1200/JCO.2003.10.066
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
F. Kabbinavar (2003)
10.1016/j.ctrv.2007.11.001
Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.
A. Eisen (2008)
10.1592/PHCO.21.20.1468.34482
Rates of Torsades de Pointes Associated with Ciprofloxacin, Ofloxacin, Levofloxacin, Gatifloxacin, and Moxifloxacin
R. Frothingham (2001)
10.1200/JCO.2005.07.040
Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab.
S. Horning (2005)
10.2165/00063030-200115030-00003
Thalidomide in Cancer
S. Singhal (2012)
10.1161/CIRCULATIONAHA.108.776831
Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics
M. Chen (2008)
10.1002/1097-0142(19851215)56:12<2765::AID-CNCR2820561208>3.0.CO;2-2
Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin
N. Vogelzang (1985)
10.1097/CAD.0b013e3283165f27
The spectrum of 5-fluorouracil cardiotoxicity
J. Dalzell (2009)
10.1186/1756-8722-1-1
Journal of hematology & oncology: A journal open to all
D. Liu (2008)
10.1182/BLOOD.V98.5.1614
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.
M. Zangari (2001)
10.1200/JCO.2005.04.937
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.
W. Gradishar (2005)
10.1093/JNCI/DJI372
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
B. Fisher (2005)
10.1186/1479-5876-6-24
Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer
T. Tsuruma (2007)
10.1182/BLOOD-2004-11-4314
No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome.
J. Lundin (2005)
5-Fluorouracil related toxic myocarditis: case reports and pathological confirmation.
Z. Sasson (1994)
10.1056/NEJMOA065044
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
R. Motzer (2007)
10.1038/sj.bmt.1703133
Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977–1997
T. Murdych (2001)
10.1158/1078-0432.CCR-08-1124
A Phase I-II Study to Determine the Maximum Tolerated Infusion Rate of Rituximab with Special Emphasis on Monitoring the Effect of Rituximab on Cardiac Function
M. Siano (2008)
10.1093/ANNONC/MDM489
Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma.
M. Mego (2007)
10.1182/BLOOD-2006-10-054080
Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation.
A. Tichelli (2007)
10.1182/BLOOD.V98.2.266
Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide.
P. Westervelt (2001)
10.1182/BLOOD.V98.2.492
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.
B. Barlogie (2001)
10.1093/ANNONC/MDH134
Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resection.
K. Patel (2004)
10.1001/ARCHINTE.1981.00340060066015
Cardiotoxicity associated with high-dose cyclophosphamide therapy.
J. Gottdiener (1981)
10.1016/S1470-2045(06)70664-7
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
M. Pfreundschuh (2006)
10.7326/0003-4819-133-11-200012050-00012
Prolongation of the QT Interval and Ventricular Tachycardia in Patients Treated with Arsenic Trioxide for Acute Promyelocytic Leukemia
K. Ohnishi (2000)
10.1158/1078-0432.CCR-08-0015
Ixabepilone in Combination with Capecitabine and as Monotherapy for Treatment of Advanced Breast Cancer Refractory to Previous Chemotherapies
R. J. Lechleider (2008)
10.1016/S1533-0028(11)70480-7
Highlights from: 5-Fluorouracil Drug Management Pharmacokinetics and Pharmacogenomics Workshop; Orlando, Florida; January 2007.
J. Bertino (2007)
10.1200/JCO.2008.18.9043
Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.
B. Monk (2009)
10.1200/JCO.2007.12.0733
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.
C. Dang (2008)
10.1093/ANNONC/MDL463
Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial.
S. Boeck (2007)
10.1182/BLOOD-2003-07-2345
Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome.
D. Lenihan (2004)
10.5555/URI:PII:0093775482900057
The cardiotoxicity of anticancer agents.
D. V. Von Hoff (1982)
10.1093/jnci/djn206
New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
M. Ryberg (2008)
10.1200/JCO.2008.26.15_SUPPL.9569
Tolerance of bevacizumab in an older patient population: The Memorial Sloan-Kettering Cancer Center (MSKCC) experience
S. Richardson (2008)
10.1200/JCO.2007.14.9930
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
L. Saltz (2008)
10.1200/JCO.2007.15.0375
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
G. Scagliotti (2008)
10.1002/1097-0142(19941215)74:12<3212::AID-CNCR2820741221>3.0.CO;2-I
Cardiopulmonary toxicity of treatment with high dose interleukin‐2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma
R. White (1994)
10.1093/annonc/mdn018
Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma.
A. Palumbo (2008)
10.1182/BLOOD-2006-04-015909
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
P. Richardson (2006)
10.1200/JCO.20.6.1491
Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer.
J. Sloan (2002)
10.1200/JCO.2007.15.6331
Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.
M. Schmidinger (2008)
10.1093/jjco/hyn139
Overview of gefitinib in non-small cell lung cancer: an Asian perspective.
H. Jiang (2009)
10.1378/CHEST.99.3.557
Cardiotoxicity of interferon. A review of 44 cases.
M. Sonnenblick (1991)
10.1200/JCO.2004.10.182
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.
L. Saltz (2004)
10.1200/JCO.1985.3.6.818
A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.
K. K. Jain (1985)
10.1016/S0140-6736(04)17666-6
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
A. Howell (2005)
10.1016/S0140-6736(05)66544-0
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
O. Abe (2005)
10.1200/JCO.2006.07.8170
Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.
L. Rosen (2007)
10.2147/TCRM.S1566
Long-term safety of aromatase inhibitors in the treatment of breast cancer
Jean-Marc A. Nabholtz (2008)
10.1053/CLON.2002.0177
Vascular toxicity associated with cisplatin.
M. King (2003)
10.1038/sj.onc.1210380
Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia
L. Alinari (2007)
10.1093/qjmed/hcn050
Advances in tumour immunotherapy.
J. King (2008)
10.1002/cncr.21326
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence
R. Larson (2005)
10.4065/83.6.679
Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials.
E. Perez (2008)
10.1158/1078-0432.CCR-07-0061
A Parallel Dose-Escalation Study of Weekly and Twice-Weekly Bortezomib in Combination with Gemcitabine and Cisplatin in the First-Line Treatment of Patients with Advanced Solid Tumors
J. Voortman (2007)
10.1016/0145-2126(94)00123-R
Cytarabine-induced pericarditis: a case report and review of the literature of the cardio-pulmonary complications of cytarabine therapy.
S. Reykdal (1995)
10.1200/JCO.1989.7.1.7
Cardiorespiratory effects of immunotherapy with interleukin-2.
R. E. Lee (1989)
10.1200/JCO.1997.15.2.808
Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.
A. de Gramont (1997)
10.1126/SCIENCE.3798106
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D. Slamon (1987)
10.1159/000186667
Acute cardiac and renal failure after 5-FU and cisplatin treatment.
G. Brillet (1991)
10.1182/BLOOD.V98.4.958
Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.
A. Raza (2001)
10.1345/aph.1C510
Electrocardiographic and Cardiovascular Effects of the 5-Hydroxytryptamine3 Receptor Antagonists
R. Navari (2003)
10.1016/S0140-6736(07)60200-1
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
R. Coombes (2007)
10.1634/THEONCOLOGIST.7-1-65
The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern?
D. Keefe (2002)
Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
M. Cohen (2002)
Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
M. Duvic (2001)
10.1161/CIRCULATIONAHA.108.799700
Acute Doxorubicin Cardiotoxicity Is Associated With p53-Induced Inhibition of the Mammalian Target of Rapamycin Pathway
W. Zhu (2009)
10.1023/A:1008380208045
Gemcitabine-induced atrial fibrillation: a hitherto unreported manifestation of drug toxicity.
D. Santini (2000)
10.7326/0003-4819-118-1-199301010-00006
High-Dose Ifosfamide Is Associated with Severe, Reversible Cardiac Dysfunction
Z. Quezado (1993)
10.1034/j.1600-0609.2002.00712.x
Severe cardiac toxicity after monoclonal antibody therapy
G. Damaj (2002)
10.1159/000073351
Side Effects of Ifosfamide
J. Klastersky (2003)
10.1080/10428190701332456
Cytosine-arabinoside induced bradycardia in patient with non-Hodgkin lymphoma: A case report
T. Çil (2007)
10.1016/S0936-6555(05)80819-2
Etoposide-related myocardial infarction.
C. L. Airey (1995)
10.1159/000225817
Supraventricular tachycardia. A probable complication of platinum treatment.
L. Hashimi (1984)
10.1007/s10549-007-9803-5
The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines
G. Dranitsaris (2007)
10.1200/JCO.2004.06.033
Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.
O. Hequet (2004)
10.1158/1078-0432.CCR-05-0539
Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy
L. Gianni (2005)
10.1038/bmt.2008.263
High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation
N. Majhail (2009)
10.1200/JCO.2007.13.0856
Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer
C. Butts (2007)
10.1007/BF00257451
Ifosfamide cardiotoxicity in humans
K. Kandylis (2004)
10.2165/00003088-198916040-00002
Clinical Pharmacology of 5-Fluorouracil
R. Diasio (1989)
10.1007/S12094-008-0150-8
Cardiac toxicity: old and new issues in anti-cancer drugs
M. Sereno (2008)
10.1200/JCO.2005.04.173
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
M. Marty (2005)
10.1016/J.BBMT.2005.07.002
Cardiac manifestations of graft-versus-host disease.
C. Rackley (2005)
10.1158/1078-0432.CCR-07-1165
Preclinical Toxicity, Toxicokinetics, and Antitumoral Efficacy Studies of DTS-201, a Tumor-Selective Peptidic Prodrug of Doxorubicin
D. Ravel (2008)
10.1200/JCO.2001.19.9.2456
Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.
M. Duvic (2001)
10.1634/THEONCOLOGIST.10-7-461
FDA drug approval summary: erlotinib (Tarceva) tablets.
M. Cohen (2005)
10.1056/NEJMOA043623
Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.
T. Winton (2005)
10.1200/JCO.2005.14.696
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.
P. Philip (2005)
10.1016/J.IJROBP.2007.07.2325
Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity.
H. Safran (2008)
10.1002/cncr.20888
Bortezomib in recurrent and/or refractory multiple myeloma
S. Jagannath (2005)
10.1056/NEJM200009283431302
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
L. Saltz (2000)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1200/JCO.1992.10.9.1386
Hypercholesterolemia after chemotherapy for testis cancer.
D. Raghavan (1992)
10.1158/1078-0432.CCR-07-2219
Vinflunine: A New Microtubule Inhibitor Agent
J. Bennouna (2008)
10.1200/JCO.2008.16.6462
Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer.
M. Barve (2008)
10.1097/01.COC.0000017782.24458.DD
Gemcitabine-Induced Peripheral Edema: Report on 15 Cases and Review of the Literature
C. Azzoli (2003)
10.1093/ANNONC/MDF132
Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients.
B. V. Jensen (2002)
10.1007/s10549-007-9610-z
Gemcitabine in the management of metastatic breast cancer: a systematic review
S. Dent (2007)
Marrow transplanation in man following cyclophosphamide.
G. Santos (1971)
10.1016/J.EJCA.2004.01.011
Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial.
M. Untch (2004)
10.1002/j.1552-4604.1993.tb01943.x
Clinical Cardiotoxicity of 5‐Fluorouracil
D. Keefe (1993)
10.1016/J.EUPC.2004.12.012
Doxorubicin-induced second degree and complete atrioventricular block.
S. Kilickap (2005)
10.1023/A:1008231521553
Cardiac arrhythmias after cisplatin infusion: three case reports and a review of the literature.
D. Tassinari (1997)
10.1038/sj.bmt.1704487
Predictors for severe cardiac complications after hematopoietic stem cell transplantation
M. Sakata-Yanagimoto (2004)
10.1200/JCO.2005.16.139
Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.
D. D’Adamo (2005)
10.1089/dis.2008.111714
Cardiovascular late effects and the ongoing care of adult cancer survivors.
J. Carver (2008)
10.1158/0008-5472.SABCS-09-62
Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.
D. Slamon (2009)
10.1093/annonc/mdn168
Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate.
M. Telli (2008)
10.1200/JCO.1998.16.11.3502
Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer.
M. Ryberg (1998)
10.1378/CHEST.99.3.667
Diagnosis of disease caused by Mycobacterium avium complex.
M. Tsukamura (1991)
10.1002/cncr.23460
Heart failure associated with sunitinib malate
A. Khakoo (2008)
10.1532/IJH97.E0620
Cardiac Toxicity of High-Dose Cyclophosphamide in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation
S. Zver (2007)
10.1016/S0140-6736(07)61865-0
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
T. F. Chu (2007)
10.1200/JCO.1991.9.1.192
Cisplatin-induced atrial fibrillation.
O. Ménard (1991)
10.1200/JCO.2007.15.5481
Predicting fluorouracil toxicity: can we finally do it?
H. Ezzeldin (2008)
10.1016/S0140-6736(80)92727-0
MYOCARDIAL INFARCTION FOLLOWING VINBLASTINE TREATMENT
J. Lejonc (1980)
10.1007/BF00397722
Reversible arrhythmias observed in patients treated with recombinant alpha2 interferon
S. Martino (2004)
10.1093/ANNONC/MDJ110
A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease.
P. Papaldo (2006)
10.1016/S1083-8791(00)70043-7
Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer.
Y. Nieto (2000)
10.1158/1078-0432.CCR-07-2201
The Epothilones: Translating from the Laboratory to the Clinic
J. Lee (2008)
10.1093/JJCO/HYI090
Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes.
M. Toi (2005)
10.3324/haematol.12949
Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation
A. Tichelli (2008)
10.1093/OXFORDJOURNALS.ANNONC.A057750
Vascular toxicity and the mechanism underlying Raynaud's phenomenon in patients treated with cisplatin, vinblastine and bleomycin.
S. Hansen (1990)
10.3816/SCT.2006.n.023
Adverse effects of bevacizumab and their management in solid tumors.
Y. Arriaga (2006)
10.1200/JCO.2007.14.5367
Lenalidomide for the treatment of B-cell malignancies.
A. Chanan-Khan (2008)
10.1007/s002770050312
Pericarditis induced by high-dose cytosine arabinoside chemotherapy
C. Hermans (1997)
10.1161/01.CIR.0000039105.49749.6F
Lifetime Risk for Developing Congestive Heart Failure: The Framingham Heart Study
D. Lloyd-Jones (2002)
10.1158/1078-0432.CCR-06-1812
A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
J. Berenson (2007)
10.1200/JCO.1994.12.5.998
Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant.
B. Hertenstein (1994)
10.1159/000098062
Thrombosis of Internal Carotid Artery after Cisplatin-Based Chemotherapy
J. Pretnar-Oblak (2006)
10.1182/BLOOD-2001-12-0245
Thromboembolic events during treatment with thalidomide.
E. Urbauer (2002)
A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.
S. Giordano (2002)
10.1056/NEJMOA031644
Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.
R. Arriagada (2004)
10.1200/JCO.2001.19.1.37
Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation.
M. Zambetti (2001)
10.1200/JCO.2008.26.15_SUPPL.2568
Final results of a phase I study of picoplatin and pegylated liposomal doxorubicin in advanced solid tumor malignancies
D. Dizon (2008)
10.1345/aph.10180
Recurrent Asymptomatic Bradycardia Episodes after Cisplatin Infusion
Ö. Altundağ (2001)
10.1046/j.1365-2141.2003.04245_2.x
Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma
Tallal Hussein Younis (2003)
10.1200/JCO.2008.18.5447
Evidence mounts for the efficacy of radioimmunotherapy for B-cell lymphomas.
O. Press (2008)
10.1093/ANNONC/MDL476
A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer.
A. Chan (2007)
10.1177/030089168206800609
Cardiac Toxicity of 5-Fluorouracil: A Study on 1083 Patients
R. Labianca (1982)
10.1200/JCO.2006.09.1611
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.
T. Suter (2007)
10.1038/nm1446
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
Risto Kerkelä (2006)
10.1001/JAMA.1991.03470120074036
Cardiac toxicity 4 to 20 years after completing anthracycline therapy.
L. Steinherz (1991)
10.1200/JCO.2007.12.9098
Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia.
P. Hillmen (2007)
10.1002/cncr.23855
Arsenic trioxide and low‐dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia
G. Roboz (2008)
10.1200/JCO.2000.18.8.1725
Cardiovascular morbidity in long-term survivors of metastatic testicular cancer.
M. T. Meinardi (2000)
10.1016/J.CANLET.2005.11.014
BNP as a marker of the heart failure in the treatment of imatinib mesylate.
Y. Park (2006)
10.1007/s12185-008-0139-7
Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib
A. Hacıhanefioğlu (2008)
10.1200/JCO.2008.17.2015
Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.
F. Morschhauser (2008)
10.1200/JCO.2005.05.1474
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.
U. Gatzemeier (2007)
10.1200/JCO.2004.03.025
How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30.
E. Fromme (2004)
10.1093/ANNONC/MDH097
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
M. O'Brien (2004)
10.1200/JCO.1999.17.8.2341
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
S. Chan (1999)
10.1093/annonc/mdn292
Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies.
D. Rayson (2008)
10.1200/JCO.2007.14.0590
Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.
H. Gómez (2008)
10.1097/00001813-200603000-00016
Gemcitabine and atrial fibrillation: a rare manifestation of chemotherapy toxicity.
D. Ferrari (2006)
10.1200/JCO.2001.19.13.3244
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.
E. Sievers (2001)
10.1093/ANNONC/MDH026
Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study.
K. Zervas (2004)
10.1136/emj.2008.060574
Coronary spasm induced by capecitabine mimicks ST elevation myocardial infarction
P. Scott (2008)
10.1056/NEJM200103153441101
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D. Slamon (2001)
10.1007/s00423-008-0393-4
Interleukin-2 immunotherapy action on innate immunity cells in peripheral blood and tumoral tissue of pancreatic adenocarcinoma patients
L. Degrate (2008)
10.1592/phco.2005.25.9.1271
Acute Cardiac Toxicity Associated with High‐Dose Intravenous Methotrexate Therapy: Case Report and Review of the Literature
A. Perez-Verdia (2005)
10.1002/1097-0142(19870915)60:6<1213::AID-CNCR2820600609>3.0.CO;2-V
Acute arrhythmogenicity of doxorubicin administration
J. Steinberg (1987)
10.1159/000163051
Gemcitabine-Induced Acute Coronary Syndrome: A Case Report
B. Ozturk (2008)
10.7326/0003-4819-146-1-200701020-00006
Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura
D. Arnold (2007)
10.1200/JCO.2005.04.120
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
F. Boccardo (2005)
10.1038/ncpcardio1352
A case of cardiogenic shock caused by capecitabine treatment
A. C. To (2008)
10.1007/S11912-008-0039-2
The current role of immunotherapy for renal cell carcinoma in the era of targeted therapeutics
M. K. Wong (2008)
10.1200/JCO.2003.04.173
Cardiovascular disease as a long-term complication of treatment for testicular cancer.
R. Huddart (2003)
10.1093/JNCI/DJM086
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
F. Scappaticci (2007)
10.7326/0003-4819-125-1-199607010-00008
Anthracycline-Induced Cardiotoxicity
K. Shan (1996)
10.1158/1055-9965.EPI-08-0570
Tamoxifen Treatment in Danish Breast Cancer Patients and 5-Year Risk of Arterial Atherosclerotic Events: A Null Association
R. Hernandez (2008)
10.1200/JCO.1993.11.12.2405
Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.
E. Trimble (1993)
10.1093/annonc/mdn060
Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy.
V. Diéras (2008)
10.1007/BF00685827
Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia
A. Wåhlin (2004)
10.1056/nejmoa0808268
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.
J. Tol (2009)
10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
Reporting results of cancer treatment
A. Miller (1981)
10.1200/JCO.20.1.205
Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.
M. Keating (2002)
10.1200/JCO.2008.17.5349
Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck.
K. Harrington (2009)
10.1016/0300-483X(95)03124-X
Immune-mediated side-effects of cytokines in humans.
T. Vial (1995)
10.1111/j.1365-2141.2007.06659.x
Unexpected cardiotoxicity in haematological bortezomib treated patients
E. Orciuolo (2007)
10.1186/bcr1407
Bone versus breast density
J. Cuzick (2006)
10.1200/JCO.2002.12.102
Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer.
S. Lipshultz (2002)
10.1016/j.critrevonc.2008.07.017
Taxanes in the elderly: can we gain as much and be less toxic?
L. Biganzoli (2009)
10.1053/J.AJKD.2006.11.039
Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.
X. Zhu (2007)
10.1200/JCO.2007.14.9401
Anthracycline cardiotoxicity: from bench to bedside.
L. Gianni (2008)
10.1200/JCO.2007.13.5467
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.
E. Perez (2008)
10.1002/cncr.23389
Cardiovascular risk in long‐term survivors of testicular cancer
D. Vaughn (2008)
10.1016/j.radonc.2008.09.018
Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer.
D. Pryor (2009)
10.1200/JCO.2006.08.8617
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
A. Coates (2007)
10.1200/JCO.2004.10.052
Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.
S. Schey (2004)
10.1002/CNCR.2820360908
Vincristine‐induced myocardial infarction
Eugen M. Mandel (1975)
10.1200/JCO.2007.11.6699
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.
A. Seidman (2008)
10.1200/JCO.2005.05.098
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
K. Miller (2005)
10.1056/NEJMra0708875
Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma.
B. Cheson (2008)
10.1002/1097-0142(197307)32:1<1::AID-CNCR2820320101>3.0.CO;2-X
Phase II evaluation of adriamycin in human neoplasia
R. O'bryan (1973)
10.1002/1097-0142(19930715)72:2<587::AID-CNCR2820720242>3.0.CO;2-V
Severe vascular toxicity associated with cisplatin‐based chemotherapy
F. Içli (1993)
10.1200/JCO.2007.14.4824
Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.
K. Kelly (2008)
10.1001/JAMA.295.21.2516
Sunitinib in patients with metastatic renal cell carcinoma.
R. Motzer (2006)
10.1200/JCO.2008.17.1637
Capecitabine-induced coronary vasospasm.
Y. Goldsmith (2008)
10.1016/S0145-2126(98)00008-3
Evidence for sinoatrial blockade associated with high dose cytarabine therapy.
K. Stamatopoulos (1998)
10.1002/ART.10947
Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy.
G. Silverman (2003)
10.1007/s004320050327
Severe non-haematological toxicity after treatment with gemcitabine
A. Sauer-Heilborn (1999)
10.3816/CLM.2006.N.050
Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma.
A. Suvannasankha (2006)
10.1200/JCO.2005.02.4091
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
E. Tan-chiu (2005)
10.1200/JCO.2003.10.009
Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
J. Barbey (2003)
10.1016/S0959-8049(01)00155-1
Effect of letrozole on the lipid profile in postmenopausal women with breast cancer.
M. Elisaf (2001)
10.1182/BLOOD-2006-05-022335
Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study.
K. Baker (2007)
10.1016/J.LEUKRES.2007.08.016
Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience.
M. Breccia (2008)
10.1200/JCO.2005.04.9551
Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.
V. Guarneri (2006)
10.1002/1097-0142(197911)44:5<1588::AID-CNCR2820440508>3.0.CO;2-X
Sudden death during doxorubicin administration
J. Wortman (1979)
10.1111/j.1540-8159.1999.tb06826.x
Complete Atrioventricular Block after Arsenic Trioxide Treatment in an Acute Promyelocytic Leukemic Patient
C. Huang (1999)
10.1097/00000421-199910000-00009
Severe cardiotoxicity during 5-fluorouracil chemotherapy: a case and literature report.
C. Kuropkat (1999)
Radionuclide ejection fractions in the evaluation of patients being considered for bone marrow transplantation: risk for cardiac toxicity.
S. Bearman (1990)
10.1200/JCO.2005.04.1764
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.
N. Robert (2006)
10.1016/J.OPHTHA.2006.05.055
A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration.
Q. Nguyen (2006)
10.1200/JCO.2006.10.4182
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.
M. Schwab (2008)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar